Defining Future Opportunities in Immunoscience
A pharmaceutical organization exploring an expansion of its immunoscience portfolio needed to understand where unmet patient needs could support future investment.
I led the engagement across psoriasis, inflammatory bowel disease, and multiple myeloma, translating patient evidence into a prioritized framework of technical, experiential, and strategic opportunities.
The work gave business and development leaders a clearer basis for opportunity prioritization and future drug-product and portfolio investment discussions across multiple immunoscience markets.
Keywords: Opportunity Identification · Portfolio Strategy · Patient Insight · Opportunity Prioritization · Investment Decision Support · Immunoscience
Project Info
Client: A Pharmaceutical Manufacturer
Time: 2019, 8 Months
Role: Engagement Lead, Strategist, Principal Investigator
Project Overview
-
We began by engaging clinical, technical, and business experts from across the organization to understand the three disease areas, clarify existing knowledge, and identify the unknowns most important to future product development.
I connected those knowledge gaps to the strategic questions facing the business and built early alignment with the stakeholders who would ultimately evaluate and act on the opportunities.
-
I guided a research program combining five-day mobile ethnography with in-depth patient and caregiver interviews to understand treatment journeys alongside the realities of living with chronic illness.
The work examined medication use, daily routines, emotional wellbeing, treatment burden, and the broader social context of care, exposing needs that conventional clinical or product analysis could miss.
-
Across the three disease states, our team synthesized more than 4,000 data points into a detailed understanding of the patient experience.
I guided the team in identifying the patterns that mattered most, looking both within individual journeys and across conditions for broader opportunity spaces relevant to future drug-product development.
We translated that complexity into journey frameworks that allowed stakeholders to see where treatment pathways, non-drug interventions, emotional needs, and everyday life intersected.
-
I brought an extended stakeholder group together in a series of in-person workshops, to connect patient evidence with the organization’s clinical, technical, and business expertise.
Rather than treating journey maps as the endpoint, I led the team in translating the evidence into an opportunity framework that allowed stakeholders to evaluate and prioritize technical, experiential, and strategic business opportunities.
The work shifted the conversation from individual product requirements toward broader questions about where unmet patient needs could justify future investment.
Key Takeaways
Looking Across Conditions
Studying psoriasis, inflammatory bowel disease, and multiple myeloma together allowed us to move beyond individual treatment journeys and identify patterns with relevance across the portfolio.
This cross-condition perspective helped the organization consider where common unmet needs could support differentiated drug products, experiences, and future investments.
Revealing the Broader Context of Care
The work showed that some of the most meaningful opportunities existed beyond the clinical treatment itself.
Diagnosis, stigma, treatment burden, emotional vulnerability, and socioeconomic circumstances all shaped how people experienced chronic illness.
Bringing those realities into the strategic conversation expanded the organization’s view of where innovation could create value.
Challenges
Leading a Complex Engagement
Three disease states moved through discovery, analysis, and opportunity development simultaneously, requiring coordination across a six-person team and a broad client stakeholder group.
I directed the work across those parallel streams while maintaining the senior client relationship and ensuring the emerging insights remained connected to the strategic questions the organization needed to answer.
Moving from Insight to Investment
A central challenge was helping a large stakeholder group move beyond absorbing findings toward making choices about where the organization could act.
I facilitated the integration of patient evidence with clinical, technical, and business expertise, helping create a shared view of which needs represented the strongest opportunities for further exploration and investment.